should 1l maintenance with parp inhibitors be given to all patients with ovarian cancer?
Published 2 years ago • 55 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
3:37
selecting patients to be treated with maintenance olaparib in the paola-1 trial
-
1:22
overcoming resistance to parp inhibition in ovarian cancer
-
3:45
parp inhibitors for ovarian cancer
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
2:31
should all platinum sensitive patients recieve parp inhibitors?
-
58:46
learn all about parp inhibitors with dr jon krell, consultant medical oncologist
-
3:09
the promising potential of parp inhibitors in ovarian cancer
-
5:19
barriers to use of parp inhibitor maintenance for patients with ovarian cancer
-
57:11
personalizing advanced ovarian cancer treatment with parp inhibitors and novel approaches
-
1:09
dr. zakashansky on repeat exposure to parp inhibitors in patients with ovarian cancer
-
59:14
parp inhibitors in ovarian cancer: clinical updates from sgo 2023
-
3:58
the potential of parp inhibitors in ovarian cancer: paola-1, prima & velia
-
1:53
parp inhibitors: game-changers for ovarian cancer patients?
-
59:02
parp inhibitors as first-line maintenance therapy in ovarian cancer
-
0:46
parp inhibitor rechallenging in ovarian cancer
-
5:55
maintenance therapy: parp inhibitor or bevacizumab
-
6:25
combinations with parp inhibitors for ovarian cancer
-
4:17
maintenance therapy in ovarian cancer: parp inhibitors
-
10:36
parp inhibitor trial updates